Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.050
+0.010 (0.49%)
Mar 16, 2026, 4:00 PM EDT - Market closed
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$3,024,176
Market Cap
6.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | 15 | -1 | -6.25% | 10 | 5 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| Quince Therapeutics | 36 |
| Dogwood Therapeutics | 12 |
| Processa Pharmaceuticals | 10 |
| Immuron | 7 |
| Mustang Bio | 6 |
| Xenetic Biosciences | 2 |
| PharmaCyte Biotech | 2 |
MBRX News
- 5 days ago - Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - GlobeNewsWire
- 25 days ago - Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - GlobeNewsWire
- 26 days ago - Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewsWire
- 27 days ago - Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - GlobeNewsWire
- 4 weeks ago - Moleculin Launches CEO Corner Platform to Share Strategic Insights - GlobeNewsWire
- 5 weeks ago - Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 2 months ago - Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - GlobeNewsWire
- 2 months ago - Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - GlobeNewsWire